BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide but there are different prevalence rates in different countries. Data on the incidence of HCV in the general population are scarce. Spontaneous viral clearance occurs in 10-25% of infected individuals after acute infection yet controversy exists regarding the frequency of spontaneous clearance during the natural course of HCV infection in the general population. AIMS: Anti-HCV prevalence, HCV infection rate, and the kinetics of anti-HCV were studied in a cross section of the general population of central Italy. STUDY POPULATION AND METHODS: Anti-HCV prevalence (EIA-3 Ortho, RIBA-3 Ortho Chiron) was estimated in 3884 randomly selected individuals. Infection rate and antibody kinetics were estimated in 2032 participants for whom a second blood sample was taken after a median follow up of seven years. HCV-RNA determination by polymerase chain reaction was performed on follow up sera. RESULTS: The overall confirmed anti-HCV prevalence was 2.4%. Two participants seroconverted for anti-HCV, giving an overall infection rate of 1.4 cases per 10 000 person years (95% confidence interval 0.2-5.2 per 10 000 person years). Of the 36 individuals confirmed as anti-HCV positive at enrollment, seven (19.4%) showed complete seroreversion. Seven (87%) of the eight individuals with indeterminate results at enrollment were serologically non-reactive at the end of follow up. Of the 25 participants confirmed to be anti-HCV positive at both enrollment and follow up, 23 (92.0%) with stable serological profiles tested positive for HCV-RNA at the end of follow up. CONCLUSIONS: There is still a permanent risk, although low, of HCV spread in the general population in an area of low level endemicity. In this setting, a wide spectrum of modifications of viral and antibody patterns can be observed in HCV infected patients.
BACKGROUND:Hepatitis C virus (HCV) infection is common worldwide but there are different prevalence rates in different countries. Data on the incidence of HCV in the general population are scarce. Spontaneous viral clearance occurs in 10-25% of infected individuals after acute infection yet controversy exists regarding the frequency of spontaneous clearance during the natural course of HCV infection in the general population. AIMS: Anti-HCV prevalence, HCV infection rate, and the kinetics of anti-HCV were studied in a cross section of the general population of central Italy. STUDY POPULATION AND METHODS: Anti-HCV prevalence (EIA-3 Ortho, RIBA-3 Ortho Chiron) was estimated in 3884 randomly selected individuals. Infection rate and antibody kinetics were estimated in 2032 participants for whom a second blood sample was taken after a median follow up of seven years. HCV-RNA determination by polymerase chain reaction was performed on follow up sera. RESULTS: The overall confirmed anti-HCV prevalence was 2.4%. Two participants seroconverted for anti-HCV, giving an overall infection rate of 1.4 cases per 10 000 person years (95% confidence interval 0.2-5.2 per 10 000 person years). Of the 36 individuals confirmed as anti-HCV positive at enrollment, seven (19.4%) showed complete seroreversion. Seven (87%) of the eight individuals with indeterminate results at enrollment were serologically non-reactive at the end of follow up. Of the 25 participants confirmed to be anti-HCV positive at both enrollment and follow up, 23 (92.0%) with stable serological profiles tested positive for HCV-RNA at the end of follow up. CONCLUSIONS: There is still a permanent risk, although low, of HCV spread in the general population in an area of low level endemicity. In this setting, a wide spectrum of modifications of viral and antibody patterns can be observed in HCV infectedpatients.
Authors: G Maio; P d'Argenio; T Stroffolini; A Bozza; L Sacco; M E Tosti; M Intorcia; E Fossi; G d'Alessio; L A Kondili; M Rapicetta; A Mele Journal: J Hepatol Date: 2000-07 Impact factor: 25.083
Authors: G Maggi; S Armitano; L Brambilla; M Brenna; M Cairo; G Galvani; D Gola; K Komla-Ebri; E Marmondi; G Perricone; M Posca; P G Vegezzi; C Vergani; G De Leo Journal: Liver Date: 1999-10
Authors: A Mele; M E Tosti; A Marzolini; A Moiraghi; P Ragni; G Gallo; E Balocchini; F Santonastasi; T Stroffolini Journal: J Viral Hepat Date: 2000-01 Impact factor: 3.728
Authors: L B Seeff; F B Hollinger; H J Alter; E C Wright; C M Cain; Z J Buskell; K G Ishak; F L Iber; D Toro; A Samanta; R L Koretz; R P Perrillo; Z D Goodman; R G Knodell; G Gitnick; T R Morgan; E R Schiff; S Lasky; C Stevens; R Z Vlahcevic; E Weinshel; T Tanwandee; H J Lin; L Barbosa Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: S Giampaoli; A Poce; F Sciarra; C Lo Noce; F Dima; A Minoprio; A Santaquilani; P Caiola de Sanctis; R Volpe; A Menditto; A Menotti; G C Urbinati Journal: Acta Cardiol Date: 1997 Impact factor: 1.718
Authors: H Okamoto; Y Sugiyama; S Okada; K Kurai; Y Akahane; Y Sugai; T Tanaka; K Sato; F Tsuda; Y Miyakawa Journal: J Gen Virol Date: 1992-03 Impact factor: 3.891
Authors: I Bakr; C Rekacewicz; M El Hosseiny; S Ismail; M El Daly; S El-Kafrawy; G Esmat; M A Hamid; M K Mohamed; A Fontanet Journal: Gut Date: 2006-01-24 Impact factor: 23.059
Authors: Su Hyun Cho; Sung Wook Lee; Seok Reyol Choi; Sang Young Han; Myung Hwan Roh; Jong Hoon Lee; Jin Seok Jang; Yang Hyun Baek; Su Young Kim Journal: Gut Liver Date: 2011-03-16 Impact factor: 4.519
Authors: Marcia Russell; Meng-Jinn Chen; Thomas H Nochajski; Maria Testa; Scott J Zimmerman; Patricia S Hughes Journal: Am J Public Health Date: 2009-02-12 Impact factor: 9.308
Authors: Yeon Seok Seo; Eun Suk Jung; Jeong Han Kim; Young Kul Jung; Ji Hoon Kim; Hyonggin An; Hyung Joon Yim; Jong Eun Yeon; Kwan Soo Byun; Chang Duck Kim; Ho Sang Ryu; Soon Ho Um Journal: Korean J Intern Med Date: 2009-11-27 Impact factor: 3.165